Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 for drug discovery and mechanism of action (MOA) research

Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Balugrastim has been used in trials studying the treatment of Solid Tumors. Neutropenia is one of the most common toxicities in cancer patients receiving myelosuppressive chemotherapy. Patients who develop neutropenia are at increased risk for infection with fever. Balugrastim is a recombinant granulocyte colony-stimulating factors (G-CSFs) reduce the incidence and duration of chemotherapy-induced neutropenia and febrile neutropenia when given as adjunct therapy to patients receiving myelosuppressive chemotherapy. Balugrastim is a long-acting G-CSF composed of a genetic fusion between recombinant human serum albumin and G-CSF.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-748-1mg	1mg	3090
GMP-Bios-INN-748-10mg	10mg	Inquiry
GMP-Bios-INN-748-100mg	100mg	Inquiry
GMP-Bios-INN-748-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7
INN Name	Balugrastim
Target	CSF3R/G-CSF-R
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - ALB (albumin, human serum albumin, HSA) 25-609 - CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF)
VD LC	Fusion - ALB (albumin, human serum albumin, HSA) 25-609 - CSF3 (colony stimulating factor 3, GCSF, granulocyte colony-stimulating factor, G-CSF)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	GlaxoSmithKline (Brentford UK) / Teva Pharmaceutical Industries Ltd (Cephalon) (Frazer PA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0